VY
VYNE
VYNE Therapeutics Inc.
$0.6738
-0.47%
$22.6M
No data for this timeframe.
Vol
Market Cap$22.6M
Cap SizeNano Cap
Inst. Holders5 funds
Inst. Value$311.1K
Inst. Activity1 buys / 1 sells
Recent Activity
May 6, 2026
earnings_calendar
VYNE Q1 2026 Earnings Scheduled — 2026-05-06
Mar 31, 2026
Insider
Zeronda Tyler sold 4,007 shares
CHIEF FINANCIAL OFFICER @ $0.5975 ($2.4K)
Mar 31, 2026
Insider
Harsch Mutya sold 4,007 shares
CHIEF LEGAL OFFICER AND GC @ $0.5975 ($2.4K)
Mar 31, 2026
Insider
Domzalski David sold 14,232 shares
PRESIDENT AND CEO @ $0.5975 ($8.5K)
Inst.
VANGUARD GROUP INC — ADD
314,545 shares ($182.4K)
Inst.
MORGAN STANLEY — NEAR_EXIT
43 shares ($25.00)
Price Targets
Historical data — last covering-analyst action Jul 2025. No current recommendation available.
$2.00 (Jul 2025)
Current $0.6738
Low $2.00
Median $2.00
High $2.00
1 analysts
$2.00
$2.00
Analyst Ratings
2Strong Buy
5Buy
3Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jul 30, 2025 | HC Wainwright & Co. | DOWNGRADE | Buy → Neutral |
| Apr 25, 2025 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Mar 6, 2025 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Feb 19, 2025 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Jan 14, 2025 | HC Wainwright & Co. | REITERATE | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current FY | $-1.10 | $-1.10 — $-1.10 | -75% YoY | 1 |
| Next FY | $-1.65 | $-1.65 — $-1.65 | -50% YoY | 1 |
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $182.4K | ADD |
| TWO SIGMA INVESTMENTS, LP | $127.6K | NEW |
| BANK OF AMERICA CORP | $973.00 | NEAR_EXIT |
| WELLS FARGO & COMPANY/MN | $38.00 | — |
| MORGAN STANLEY | $25.00 | NEAR_EXIT |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Mar 31, 2026 | Zeronda Tyler | F | $2.4K |
| Mar 31, 2026 | Harsch Mutya | F | $2.4K |
| Mar 31, 2026 | Domzalski David | F | $8.5K |
| Mar 31, 2026 | Stuart Iain | F | $1.7K |
5 institutional holders with $311.1K total value (536,330 shares) as of 2025-Q4. Top holders: VANGUARD, TWO, BANK.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 314,545 | $182.4K | 58.6% | ADD +65.2% |
| 2 | TWO SIGMA INVESTMENTS, LP | 220,000 | $127.6K | 41.0% | NEW |
| 3 | BANK OF AMERICA CORP /DE/ | 1,677 | $973.00 | 0.3% | NEAR_EXIT -91.4% |
| 4 | WELLS FARGO & COMPANY/MN | 65 | $38.00 | 0.0% | — |
| 5 | MORGAN STANLEY | 43 | $25.00 | 0.0% | NEAR_EXIT -95.3% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| VANGUARD GROUP INC | ADD | 190,383 | 314,545 | +65.2% | $182.4K | 2025-Q4 |
| MORGAN STANLEY | NEAR_EXIT | 911 | 43 | -95.3% | $25.00 | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | NEW | — | 220,788 | — | $74.0K | 2025-Q3 |
| VANGUARD GROUP INC | TRIM | 496,297 | 190,383 | -61.6% | $63.8K | 2025-Q3 |
| MORGAN STANLEY | TRIM | 3,411 | 911 | -73.3% | $305.00 | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 10,543 | 0 | -100.0% | $0.00 | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | NEAR_EXIT | 115,143 | 10,543 | -90.8% | $17.4K | 2025-Q2 |
| MORGAN STANLEY | TRIM | 12,811 | 3,411 | -73.4% | $5.6K | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | NEAR_EXIT | 17,163 | 1,469 | -91.4% | $2.4K | 2025-Q2 |
| UBS Group AG | EXIT | 7,576 | 0 | -100.0% | $0.00 | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 24,943 | 115,143 | +361.6% | $181.9K | 2025-Q1 |
| MORGAN STANLEY | DOUBLED | 4,299 | 12,811 | +198.0% | $20.2K | 2025-Q1 |
| UBS Group AG | DOUBLED | 631 | 7,576 | +1100.6% | $12.0K | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 86,643 | 24,943 | -71.2% | $83.6K | 2024-Q4 |
| MORGAN STANLEY | DOUBLED | 1,799 | 4,299 | +139.0% | $14.4K | 2024-Q4 |
| UBS Group AG | DOUBLED | 14 | 631 | +4407.1% | $2.1K | 2024-Q4 |
4 unique insiders with 0 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Mar 31, 2026 | Zeronda Tyler | CHIEF FINANCIAL OFFICER | F | 4,007 | $0.5975 | $2.4K |
| Mar 31, 2026 | Harsch Mutya | CHIEF LEGAL OFFICER AND GC | F | 4,007 | $0.5975 | $2.4K |
| Mar 31, 2026 | Domzalski David | PRESIDENT AND CEO | F | 14,232 | $0.5975 | $8.5K |
| Mar 31, 2026 | Stuart Iain | CHIEF SCIENTIFIC OFFICER | F | 2,876 | $0.5975 | $1.7K |
No SEC filing reports analyzed yet. Reports are generated when new filings are detected and processed by the LLM pipeline.
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution (last covering-analyst action Jul 2025): 70% buy across 10 analysts — 2 strong buy, 5 buy, 3 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Jul 2025. No current recommendation available.
$2.00 mean target (Jul 2025)
$2.00 Low
$2.00 High
| Metric | Value |
|---|---|
| Current Price | $0.6738 |
| Target Low | $2.00 |
| Target Mean | $2.00 |
| Target Median | $2.00 |
| Target High | $2.00 |
| # Analysts | 1 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-03-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY 2026-12-31 |
$-1.10 | $-1.10 | $-1.10 | -74.6% | +0.0% | 1↑ 0↓ | $0.0B | -100.0% | 1 |
| Next FY 2027-12-31 |
$-1.65 | $-1.65 | $-1.65 | -50.0% | +0.0% | 0↑ 1↓ | $0.0B | 0.0% | 1 |
3 analyst firms have rated this stock: 0 upgrades, 1 downgrades, 1 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jul 30, 2025 | HC Wainwright & Co. | DOWNGRADE | Buy | Neutral |
| Apr 25, 2025 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Mar 6, 2025 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Feb 19, 2025 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Jan 14, 2025 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Jan 6, 2025 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Dec 23, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Nov 18, 2024 | BTIG | INITIATE | — | Buy |
| Nov 8, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Sep 12, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Aug 15, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Jun 14, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Jun 5, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| May 9, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| May 6, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Feb 29, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Oct 30, 2023 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Aug 14, 2023 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| May 12, 2023 | Cantor Fitzgerald | MAINTAIN | — | Overweight |
| May 12, 2023 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Apr 19, 2023 | HC Wainwright & Co. | REITERATE | — | Buy |
| Mar 30, 2023 | HC Wainwright & Co. | REITERATE | — | Buy |
| Mar 14, 2023 | HC Wainwright & Co. | REITERATE | — | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| May 1, 2026 | 2 | 5 | 3 | 0 | 0 | 70% | |
| Apr 1, 2026 | 2 | 5 | 3 | 0 | 0 | 70% | |
| Mar 1, 2026 | 2 | 5 | 3 | 0 | 0 | 70% | |
| Feb 1, 2026 | 2 | 5 | 3 | 0 | 0 | 70% | |
| Jan 1, 2026 | 2 | 5 | 3 | 0 | 0 | 70% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 6, 2026
earnings_calendar
VYNE Q1 2026 Earnings Scheduled — 2026-05-06
Apr 21, 2026
Clinical Trial
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VYN201 Gel in Subjects With Non-segmental Vitiligo.
Phase Phase 2 — TERMINATED
Mar 4, 2026
earnings_calendar
VYNE Q4 2025 Earnings After Market Close — 2026-03-04